Dalgic, Ozden O.
Samur, Sumeyye
Spaulding, Anne C.
Llerena, Susana
Cobo, Carmen
Ayer, Turgay
Roberts, Mark S.
Crespo, Javier
Chhatwal, Jagpreet http://orcid.org/0000-0001-8741-4430
Funding for this research was provided by:
National Science Foundation (1722906, 1722614, 1722665)
Gilead Sciences
Article History
Received: 6 May 2019
Accepted: 14 October 2019
First Online: 14 November 2019
Competing interests
: <i>Spaulding</i> has accepted honoraria for speaking engagements from third-party entities funded by Abbvie, Gilead Sciences and Merck; no commercial entity had input on the content of the talks. <i>Crespo</i> has received consultancy and lecture fees from AbbVie, Celgene, Gilead Sciences, Intercept, Janssen and Merck Sharp & Dohme, Novartis. <i>Crespo</i> received grant support from AbbVie, Celgene, Intercept. <i>Ayer</i> has received consulting fee from Merck and Gilead. <i>Chhatwal</i> has received research grants and consulting fee from Gilead and Merck. All other authors have nothing to disclose in the past 12 months.